INH in the intensive along with extension phases of treatment

more potent than 1 in a number of cell lines spreading in numerous tumor types, especially in ovarian tumor IGROV1 and breast tumor MDA MB 231 cell lines. In comparison, element 11 shows a complete score of 48/96. Depending on these data, we chose to examine further the toxicity of compound 9 and 11. In vivo toxicity of compounds Erlotinib 9 and 11 Compound 1 side effects are a major limitation for its use within antitumor therapy. Thus, we determined experimentally the amounts at which compounds 9 and 11 could be safely dosed to rats upon both chronic and acute schedules and using intravenous and intraperitoneal administration routes. When testing recurring amounts via intravenous administration every 2 or 3 times for 8 cycles, the MTD for 1 is 0. Ergo, it is clearly established that higher doses of compound 9 could be safely given to mice in comparison to 1, especially in a repeated dose schedule using intravenous injection. This is the preferred style of administration, since humans will soon be dosed intravenously, thus these data can be used as the starting place for an extensive toxicology evaluation system. Pharmacokinetic Cellular differentiation studies of compounds 1 and 9 Plasma levels of compounds 1 and 9 were quantified after intravenous injections at doses of 1 and 18 mg/kg, respectively. The focus of both substances in the bloodstream dropped significantly with time, following similar kinetics. Plasma levels of compound 9 were between 5 and 20 fold higher-than compound 1, reflecting the various amounts injected initially. After 5 min plasma levels of compounds 1 and 9 were around 2,7 and 28 uM, respectively. After 30 min, the amount of compound 1 was approximately 0,2 uM and that of compound 9 of 1,7 uM. After 120 min, levels of both materials were below Icotinib 0,1 uM. In accordance with these data, body approval does not seem responsible for the differences in toxicity found for both materials. Inhibition of growth of subcutaneous colon and melanoma xenografts by compound 9 Since compound 9 showed the highest antitumor activity in vivo and the lowest toxicity, we chose to analyze its antitumor activity in more detail using subcutaneous tumor xenografs of COLO 205 colon cancer cells and SK MEL 2 melanoma cells, because these are well founded tumor models and their GI50 are near to the average price for the NCI 60 screen.